Soros Fund Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Soros Fund Management’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,237	Closed	-$610K	–	317
2021 Q1	$610K	Buy	+23,237	New	+$1.06M	0.01%	220

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Soros Fund Management's EVFM Position: Q2 2021 in Review

Soros Fund Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 23,237 shares — an estimated $610K sold.

Soros Fund Management first reported a position in EVFM in Q1 2021 and held it in 1 quarter. The position peaked at $610K in Q1 2021. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

Soros Fund Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Soros Fund Management sold 23,237 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $610K.
Soros Fund Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
Soros Fund Management's Evofem Biosciences, Inc. Common Stock position peaked at $610K in Q1 2021.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Soros Fund Management's 13F filing for Q2 2021, filed 13 Aug 2021.